Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session.
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.
The agreement provides Johnson & Johnson's pharmaceutical products an exemption from tariffs, the company said.
Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trump's administration to cut drug prices for Americans in exchange for exemptions from U.S. tariffs.
JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.
J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.
J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $204.31, denoting a -1.47% move from the preceding trading day.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CNBC's "Mad Money" host is waving the yellow flag.